NICE Rejects Roche’s Avastin For Ovarian Cancer Due To Excessive Cost

 
• By Faraz Kermani

Roche’s extremely high price for Avastin results in yet another knock-back by Britain’s NICE, this time for advanced ovarian cancer.

More from Europe

More from Geography